Finanzen von Revvity Inc (RVTY)RVTYRevvity Inc

Revvity, Inc. (RVTY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Life sciences, accounting for 50.9% of total sales, equivalent to $361.85M. Another important revenue stream is Diagnostics. Understanding this composition is critical for investors evaluating how RVTY navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Revvity, Inc. maintains a gross margin of 57.13%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 17.51%, while the net margin is 7.33%. These profitability ratios, combined with a Return on Equity (ROE) of 3.21%, provide a clear picture of how effectively RVTY converts its operational activities into shareholder value.

In the context of the broader market, RVTY competes directly with industry leaders such as ZBH and STE. With a market capitalization of $17.56B, it holds a significant position in the sector. When comparing efficiency, RVTY's gross margin of 57.13% stands against ZBH's 63.30% and STE's 45.58%. Such benchmarking helps identify whether Revvity, Inc. is trading at a premium or discount relative to its financial performance.

Revvity has shown consistent revenue growth, with Q2 2026 revenue at $711 million, exceeding expectations. The gross margin has improved to 57.13%, indicating strong operational efficiency. Net income for Q2 2026 was $51.82 million, reflecting effective cost management and growth in demand, particularly in AI-related orders.